EE510 An Economic Model to Evaluate the Impact of Formulary Tier Increases for Apixaban on the Incidence and Cost of Clinical Events in Patients with Non-Valvular Atrial Fibrillation in the United States
Abstract
Authors
Rupesh Subash Elisabeth Vodicka Serina Deeba Vasileios Vasilopoulos Carissa Dickerson Ewa Stawowczyk